Cardiovascular Systems Inc: management transactions · United States · SEC (Form 4)

About Cardiovascular Systems Inc

Cardiovascular Systems Inc. (ticker: CSII) was a U.S.-based medical device company focused on the treatment of complex artery disease, with a particular emphasis on coronary and peripheral vascular interventions. The company was listed in the United States on the NASDAQ market and was headquartered in St. Paul, Minnesota, United States. For investors, an important current-context point is that CSII is no longer an independent publicly traded company: it was acquired by Abbott and absorbed into Abbott’s broader vascular and cardiovascular portfolio. Founded in the 1980s, Cardiovascular Systems built its business around a specialized niche in interventional cardiology and endovascular therapy. Its core mission was to address heavily calcified arterial disease, a clinically challenging category in which procedural precision, patient safety, and physician adoption are critical. The company’s products were designed to help physicians modify plaque and prepare lesions in coronary and peripheral arteries, supporting interventional procedures performed in cath labs and vascular treatment centers. From a competitive standpoint, CSII was best understood as a focused specialist rather than a broad-based medtech platform. That specialization gave it differentiation versus larger diversified medical device peers, particularly in more complex cases where conventional tools may be less effective. Its market position depended on a combination of clinical utility, installed base, reimbursement dynamics, and physician familiarity. As with many regulated medtech names, growth required lengthy clinical validation, strong relationships with hospitals, and sustained investment in product development and commercial education. Geographically, the company was primarily anchored in the U.S. market, although its products belonged to a category with international relevance across developed healthcare systems. Its customer base consisted mainly of hospitals, interventional cardiologists, and vascular specialists treating arterial disease. The most significant recent development is Abbott’s acquisition of Cardiovascular Systems. Abbott has publicly stated that the acquisition expands its vascular offerings and adds technologies aimed at treating artery disease. That transaction is the key event investors should keep in mind when reading historical CSII news flow, including SEC Form 4 insider transaction filings, because the company’s equity story has effectively ended as a standalone listing and moved into Abbott’s larger medical device strategy. In short, CSII was a niche U.S. medtech company, formerly listed on NASDAQ in the United States, with a focused product set and a strategic endpoint in Abbott’s cardiovascular expansion.